Effectiveness of Convalescent Plasma Therapy in Treating COVID-19: an Evidence-based Case Report
Keywords:
convalescent plasma, coronavirus, COVID-19, SARS-CoV-2Abstract
Background: Convalescent plasma is a potentially beneficial, tolerable, and available additional treatment option for COVID-19. This study aims to evaluate whether the administration of convalescent plasma therapy leads to improved clinical outcomes in COVID-19 patients compared to standard medical therapy. Methods: We conducted a search of Pubmed, Cochrane, and EBSCO for studies assessing the clinical question using inclusion and exclusion criteria. Selected studies were critically appraised, and the results were summarized. Results: A meta-analysis of 10 randomized clinical trials (RCTs), an RCT, a case-control clinical study were selected and assessed. Only the case-control clinical study showed that convalescent plasma administration improved the clinical outcomes of patients with COVID-19, including all-cause mortality, hospital length of stay, and the need for mechanical ventilation. On the contrary, the other two studies of a higher level of evidence showed no significant clinical outcome improvement with convalescent plasma therapy. Conclusion: The effectiveness of convalescent plasma therapy in improving clinical outcomes of patients with COVID-19 was still inconclusive due to several study limitations and other possible causes.References
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;92:1475–83. doi: 10.1002/jmv.25961
Burhan E, Susanto AD, Nasution SA, et al. Pedoman tatalaksana COVID-19. 3rd ed. In: Burhan E, Susanto AD, Isbaniah F, et al., editor. Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI, IDAI; 2020.
Zuo Z, Wu T, Pan L, et al. Modalities and mechanisms of treatment for Coronavirus disease 2019. Front Pharmacol. 2021;11:1–19. doi: 10.3389/fphar.2020.583914
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8. doi: 10.1016/j.cell.2020.02.052
Franchini M, Liumbruno GM. Convalescent plasma for the treatment of severe COVID-19. Biol Targets Ther. 2021;15:31–8. doi: 10.2147/btt.s272063
Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev [Internet]. 2020;19:102554. Available from: https://doi.org/10.1016/j.autrev.2020.102554 doi: 10.1016/j.autrev.2020.102554
Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757–65. doi: 10.1172/JCI138745
Pérez-Cameo C, Marín-Lahoz J. Serosurveys and convalescent plasma in COVID-19. E Clinical Medicine. 2020;23:10–1. doi: 10.1016/j.eclinm.2020.100370
Atal S, Fatima Z. IL-6 Inhibitors in the treatment of serious COVID-19: A promising therapy? Pharmaceut Med [Internet]. 2020;34:223–31. Available from: https://doi.org/10.1007/s40290-020-00342-z doi: 10.1007/s40290-020-00342-z
Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA - J Am Med Assoc. 2021;325:1185–95. doi: 10.1001/jama.2021.2747
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of vonvalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2020;619–29. doi: 10.1056/nejmoa2031304
Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610–8. doi: 10.1056/nejmoa2033700
Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening covid-19: a randomized clinical trial. JAMA - J Am Med Assoc. 2020;324:460–70. doi: 10.1001/jama.2020.10044
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:1–10. doi: 10.1136/bmj.m3939
Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021;18:e1003415. doi: 10.1371/journal.pmed.1003415
Abolghasemi H, Eshghi P, Majid A, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020;59(5): 102.
Joyner MJ, Wright RS, Fairweather DL, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. medRxiv. 2020;1–26. doi: 10.1101/2020.05.12.20099879
Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95:1888–97. doi: 10.1016/j.mayocp.2020.06.028
U.S. National Library of Medicine. Clinicaltrials.gov [Internet]. 2021 [cited 2021 Mar 29]. Available from: https://www.clinicaltrials.gov/ct2/results?recrs=&cond=Covid19&term=convalescent+plasma&cntry=&state=&city=&dist=
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
